Inozyme Pharma, Inc.
INZY
$1.62
$0.4133.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.50M | 21.13M | 20.90M | 19.72M | 19.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 104.03M | 99.67M | 92.89M | 81.62M | 74.25M |
| Operating Income | -104.03M | -99.67M | -92.89M | -81.62M | -74.25M |
| Income Before Tax | -102.02M | -96.49M | -88.56M | -77.11M | -71.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -102.02 | -96.49 | -88.56 | -77.11 | -71.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.02M | -96.49M | -88.56M | -77.11M | -71.17M |
| EBIT | -104.03M | -99.67M | -92.89M | -81.62M | -74.25M |
| EBITDA | -103.29M | -98.90M | -92.11M | -80.81M | -73.41M |
| EPS Basic | -1.62 | -1.55 | -1.46 | -1.37 | -1.39 |
| Normalized Basic EPS | -1.02 | -0.97 | -0.91 | -0.85 | -0.85 |
| EPS Diluted | -1.63 | -1.55 | -1.46 | -1.37 | -1.39 |
| Normalized Diluted EPS | -1.02 | -0.97 | -0.91 | -0.85 | -0.85 |
| Average Basic Shares Outstanding | 251.24M | 248.87M | 242.35M | 225.27M | 207.21M |
| Average Diluted Shares Outstanding | 251.24M | 248.87M | 242.35M | 225.27M | 207.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |